Cargando…
A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma
Unique features and treatment effects of trabectedin are presented in consideration of soft tissue sarcoma management. A prolonged time on trabectedin through 59 cycles is shown. This is one of the longer reported uses of trabectedin successfully to control disease. Adjunctive cytoreduction options...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383654/ https://www.ncbi.nlm.nih.gov/pubmed/34434451 http://dx.doi.org/10.14740/jmc3655 |
_version_ | 1783741781292089344 |
---|---|
author | Reuben, Daniel Y. |
author_facet | Reuben, Daniel Y. |
author_sort | Reuben, Daniel Y. |
collection | PubMed |
description | Unique features and treatment effects of trabectedin are presented in consideration of soft tissue sarcoma management. A prolonged time on trabectedin through 59 cycles is shown. This is one of the longer reported uses of trabectedin successfully to control disease. Adjunctive cytoreduction options with surgery, radiation or ablation are presented. Future studies would be helpful to investigate treatment holidays, the impact of multi-modality care and assessment of genetics of clonal metastases. This may assist in guiding and selecting patients for priority treatment with trabectedin. |
format | Online Article Text |
id | pubmed-8383654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-83836542021-08-24 A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma Reuben, Daniel Y. J Med Cases Case Report Unique features and treatment effects of trabectedin are presented in consideration of soft tissue sarcoma management. A prolonged time on trabectedin through 59 cycles is shown. This is one of the longer reported uses of trabectedin successfully to control disease. Adjunctive cytoreduction options with surgery, radiation or ablation are presented. Future studies would be helpful to investigate treatment holidays, the impact of multi-modality care and assessment of genetics of clonal metastases. This may assist in guiding and selecting patients for priority treatment with trabectedin. Elmer Press 2021-04 2021-02-08 /pmc/articles/PMC8383654/ /pubmed/34434451 http://dx.doi.org/10.14740/jmc3655 Text en Copyright 2021, Reuben https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Reuben, Daniel Y. A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma |
title | A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma |
title_full | A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma |
title_fullStr | A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma |
title_full_unstemmed | A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma |
title_short | A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma |
title_sort | prolonged response and characteristics of trabectedin treatment of metastatic soft tissue sarcoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383654/ https://www.ncbi.nlm.nih.gov/pubmed/34434451 http://dx.doi.org/10.14740/jmc3655 |
work_keys_str_mv | AT reubendaniely aprolongedresponseandcharacteristicsoftrabectedintreatmentofmetastaticsofttissuesarcoma AT reubendaniely prolongedresponseandcharacteristicsoftrabectedintreatmentofmetastaticsofttissuesarcoma |